Bykova Aleksandra, Serova Maria, Chashkina Maria, Kosharnaya Raisa, Salpagarova Zukhra, Andreev Denis, Giverts Ilya
Department of Cardiology, Functional and Ultrasound Diagnostics of NV Sklifosovsky Institute for Clinical Medicine, IM Sechenov First Moscow State Medical University (Sechenov University) Moscow, Russia.
Department of Medical Informatics, Scientific Research Institute for System Analysis of the Russian Academy of Sciences Moscow, Russia.
Card Fail Rev. 2024 Oct 16;10:e14. doi: 10.15420/cfr.2024.06. eCollection 2024.
This review examines the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on different heart failure phenotypes with preserved ejection fraction (HFpEF). Traditional heart failure treatment modalities have shown limited success in improving outcomes for patients with HFpEF, but new evidence suggests that GLP-1RAs could be beneficial. The positive effects of GLP-1RAs are likely due to their ability to reduce systemic inflammation, enhance metabolism and directly affect the cardiovascular system, addressing critical aspects of HFpEF pathology. However, the exact impact of GLP-1RAs on clinical outcomes for different HFpEF phenotypes is still unclear. This review highlights both the potential benefits and the current limitations of GLP-1RA therapy, suggesting a careful approach for their application in clinical practice.
本综述探讨胰高血糖素样肽-1受体激动剂（GLP-1RAs）对射血分数保留的不同心力衰竭表型（HFpEF）的影响。传统的心力衰竭治疗方式在改善HFpEF患者的预后方面成效有限，但新证据表明GLP-1RAs可能有益。GLP-1RAs的积极作用可能归因于其降低全身炎症、增强代谢以及直接影响心血管系统的能力，这些作用针对了HFpEF病理生理学的关键方面。然而，GLP-1RAs对不同HFpEF表型临床结局的确切影响仍不明确。本综述强调了GLP-1RA治疗的潜在益处和当前局限性，提示在临床实践中应用时需谨慎。
